Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report) fell 13.3% during mid-day trading on Monday . The stock traded as low as $0.26 and last traded at $0.26. 222 shares traded hands during trading, a decline of 67% from the average session volume of 670 shares. The stock had previously closed at $0.30.
Zelira Therapeutics Stock Down 13.3%
The business’s fifty day simple moving average is $0.32 and its 200 day simple moving average is $0.35.
About Zelira Therapeutics
Zelira Therapeutics Ltd is a clinical-stage biotechnology company focused on the development and commercialization of proprietary cannabinoid-based therapies. The company leverages a portfolio of clinical and preclinical drug candidates designed to address unmet medical needs in areas such as chronic pain, autism spectrum disorder, Alzheimer’s disease and sleep disorders. Utilizing patented formulation and delivery platforms, Zelira aims to optimize efficacy and safety profiles of plant-derived cannabinoids.
The company pursues a dual geography strategy through its Australian and North American operations.
Further Reading
- Five stocks we like better than Zelira Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Zelira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zelira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
